Paper Review Records
All Paper Review Records
14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
336
days
Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas
Authors
Jane E. Rogers; Ashley Horak; Alicia Kroll; Jaffer A. AjaniShow moreShow less
Affiliations
1. U.T. M.D. Anderson Cancer Center; 2. U.T.M.D. Anderson Cancer CenterShow moreShow less
195
days
At the forefront of gene-based therapies in Dravet syndrome
Authors
Antonella Riva; Sara Di Gioacchino; Greta Volpedo; Beatrice Risso; Antonella De Lillo; Federico Zara; Antonio Falace; Pasquale StrianoShow moreShow less
Affiliations
1. University of Genoa; 2. IRCCS Istituto “Giannina Gaslini”, Full Member of ERN EpiCAREShow moreShow less
29
days
σ 1 receptor agonists: the new trend or an emerging therapeutic option?
Authors
Tangui MauriceShow moreShow less
Affiliations
1. University of Montpellier, EPHE, INSERMShow moreShow less
236
days
Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease
Authors
Madia Lozupone; Vittorio Dibello; Rodolfo Sardone; Roberta Zupo; Fabio Castellana; Ilaria Bortone; Luisa Lampignano; Michela Di Matteo; Giuseppe Moramarco; Flora Dellegrazie; Antonio Daniele; Vincenzo Solfrizzi; Francesco PanzaShow moreShow less
Affiliations
1. Local Health Authority of Bari; 2. University of Bari Aldo Moro; 3. University of Bari “Aldo Moro”; 4. University of Amsterdam and Vrije Universiteit Amsterdam; 5. Local Healthcare Authority of Taranto; 6. Local Healthcare Authority of Bari; 7. Catholic University of Sacred Heart; 8. IRCCS Fondazione Policlinico Universitario A. GemelliShow moreShow less
87
days
Obefazimod (ABX464) for moderate-to-severe Crohn’s disease: clinical development of a novel oral therapeutic approach
Authors
Sailish Honap; Axel Dignass; Vipul Jairath; Fernando Magro; Silvio Danese; Laurent Peyrin-BirouletShow moreShow less
Affiliations
1. St George’s University Hospitals NHS Foundation Trust; 2. King’s College London; 3. Goethe University; 4. Western University; 5. Faculdade de Medicina da Universidade do Porto; 6. IRCCS Ospedale San Raffaele; 7. McGill University Health CentreShow moreShow less
77
days
Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond
Authors
Carolyn J. Wang; Clarus Leung; Don D. SinShow moreShow less
Affiliations
1. St. Paul’s Hospital; 2. The University of Western Australia; 3. University of British ColumbiaShow moreShow less
FAQ
How long does EXPERT OPINION ON EMERGING DRUGS take to review a manuscript?
As of 2026-11-19, CrushSCI has 14 complete review records for EXPERT OPINION ON EMERGING DRUGS. The fastest paper went from submission to acceptance in 29 days (σ 1 receptor agonists: the new trend or an emerging therapeutic option?, received 2026-05-28, accepted 2026-06-26); the slowest took 420 days. The average is 150.1 days and the median is 91 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
